Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03682640
Other study ID # AIDIT
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 2018
Est. completion date December 31, 2021

Study information

Verified date September 2018
Source Uppsala University
Contact Olle Korsgren, MD, PhD
Phone +46176114187
Email olle.korsgren@igp.uu.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Increasing evidences suggest that infections are important etiological factors for the development of Type 1 Diabetes (T1D). The overall hypothesis of the study is that the treatment of children, during the first year after diagnosis of T1D with Azithromycin, combined with repeated episodes of intensified insulin treatment to induce maximal beta-cell rest, and dietician support to promote dietary habits that minimize the likelihood of bacterial reflux from the duodenum to the pancreatic duct, will lead to preservation of beta cell function.

This trial will examine whether the AIDIT protocol initiated within one week from diagnosis could preserve insulin production in children with Type 1 Diabetes.


Description:

The study is a 2-arm, randomized, open, single center, clinical trial. Eligible patients with type 1 diabetes will be randomized to the AIDIT protocol or treatment as usual (TAU).

All patients diagnosed with T1D and included in the study will receive standard of care. In addition, the AIDIT protocol will include 1) treatment with Azithromycin for 52 weeks using a protocol for children with cystic fibrosis, 2) repeated treatments with intensified supervised high dose insulin infusion, and 3) extra advice and support from the study dietician.

1. Azithromycin Azithromycin will be administered orally. Azithromycin will be given three times per week for 52 weeks. The dose will be 500 mg for children with body weight ≥ 30 kg and 250 mg if body weight < 30 kg.

2. Intensified supervised high dose insulin infusions Participants will, in addition to Azithromycin, also be subjected to intensified anti-diabetic treatment to achieve increased beta-cell rest. This will be achieved by insulin lispro given as a supervised iv infusion for 72 hours within one week of diagnosis and by subcutaneous infusion 6-8 hours during one day in study week 5, 9, 13, 17 (±1 week) and 25, 34, 43 (±2 weeks) after inclusion. The intensified treatments will aim to target a blood glucose level of 4.0 ± 0.5 mmol/l. The efficacy of the intended maximal beta cell rest will be evaluated by measurement of plasma glucose and endogenous C-peptide. If C-peptide remains positive during the supervised infusion of insulin lispro this will be interpreted as that the insulin dose needs to be increased at the next treatment occasion to achieve beta-cell rest.

3. Dietician support Participants will receive extra advice and support from the study dietician within the first week after randomization, and after 7 and 17 weeks. Personalized nutritional advice on intake of carbohydrates, fat and protein based on four-day food records will be given to in order to reduce insulin resistance and insulin need in accordance with ISPAD guidelines. By giving nutritional advices on less volume of the meals, especially of the fluid (maximum 300 ml per meal), and by trying to extend the meal time to at least 20 minutes, the reflux into ductus pancreaticus might be reduced.

All patients will be offered an examination of their pancreas with MRI at 0 and 12 months after inclusion. In addition, plasma samples taken at inclusion and after 1.5 and 12 months will be analysed for the presence of cell-free DNA indicating ongoing cell destruction. Cell-specific methylation patterns of this cell-free DNA will be analysed to determine cell-type specific cell death.

The effect of the addition of treatment according to the AIDIT protocol will be evaluated with a Mixed Meal Tolerance Test (MMTT) to explore the effect on preservation of beta-cell function.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 72 Months to 192 Months
Eligibility Inclusion Criteria:

1. Clinically diagnosed Type 1 Diabetes. First injection of insulin maximum ten days prior to inclusion.

2. Must be willing and capable of taking the study drugs, perform tests and follow up as described as judged by the investigator.

3. Signed informed consent and expected cooperation of the patients for the treatment and follow up.

4. Aged 6.00 -15.99 years at inclusion.

5. Females of childbearing potential must agree to avoid pregnancy during the study period (by abstinence from heterosexual intercourse, or by hormonal or barrier contraception) and have a negative urine pregnancy test.

Exclusion Criteria:

1. Other diabetes diagnosis than Type 1 diabetes as judged by the investigator

2. Severe ketoacidosis (DKA) with lowest pH <7.1 within 36 hours from diagnosis.

3. Treatment with any oral or injected anti-diabetic medications other than insulin

4. Significantly abnormal haematology results at screening.

5. Participation in other clinical trials with a new chemical entity within the previous 3 months.

6. Obesity at diagnosis (Iso-BMI = 30 kg/m2 according to http://www.rikshandboken-bhv.se).

7. Other autoimmune disease present at inclusion that in the opinion of the investigator would interfere with the study protocol.

8. Celiac disease present at diagnosis.

9. Treatment with medication known to affect glucohomeostasis, i.e. glucocorticoids (inhaled, nasal or skin topic will be accepted), statins, ACE inhibitors.

10. Pregnancy or lactation

11. Known gastro-intestinal malabsorption disorders

12. Abnormalities in ECG or known cardiac disease

13. Known hearing defects

14. Known hypersensitivity to penicillin

15. Inability or unwillingness to comply with the provisions of this protocol

16. Presence of serious disease or condition in patient or family, which in the opinion of the investigator makes the patient non-eligible for the study.

17. Known renal or hepatic impairment

Study Design


Intervention

Drug:
Azithromycin Monohydrate
Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
Insulin Lispro
Solution for intravenous or subcutaneous use
Behavioral:
Dietician support
Dietary advice

Locations

Country Name City State
Sweden The Queen Silvia Children's Hospital / Sahlgrenska University Hospital Gothenburg

Sponsors (2)

Lead Sponsor Collaborator
Uppsala University Göteborg University

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Stimulated C-peptide during an MMTT Residual insulin secretion measured by mixed meal tolerance test (MMTT) stimulated C-peptide two-hour under the curve profile measured one year after study inclusion. 12 months after inclusion
Secondary >60% of time in target blood glucose levels Proportion of subjects with time in target 3.9-7.8 mmol/L = 60% and with a glycaemic variability expressed as standard deviation < 2 mmol/L according to continuous glucose monitoring during two weeks in the 12th month after initiation of the study treatment. two weeks in the 12th month after initiation of the study treatment
Secondary Time in target blood glucose levels Time in target (3.9-7.8 mmol/L) during 30 days in the 12th month after initiation of the study treatment. 30 days in the 12th month after initiation of the study treatment
Secondary Time in range blood glucose levels Time in range (3.9-10 mmol/L) during 30 days in the 12th month after initiation of the study treatment. 30 days in the 12th month after initiation of the study treatment
Secondary Insulin dose Mean daily insulin dosage per kilo bodyweight during 30 days in the 12th month after initiation of the study treatment. 30 days in the 12th month after initiation of the study treatment
Secondary HbA1c levels HbA1c at 12 months after study initiation 12 months
Secondary Hypoglycaemic events Number of severe hypoglycaemic events (hypoglycaemia level 3) during the study year. From study start to 12 months
Secondary Time in hypoglycemic range Time in hypoglycaemic range level 1 and 2 (<3.9 mmol/l and <3.0 mmol/l) respectively in CGM registrations during 30 days in the 12th month after initiation of the study treatment. 30 days in the 12th month
Secondary IDAA1c Insulin-dose-adjusted HbA1c (IDAA1c) 12 months after study initiation 12 months
Secondary Pro-insulin/c-peptide Pro-insulin/c-peptide ratio in serum 12 months after study initiation 12 months
Secondary Pancreas inflammation Inflammation in the pancreas measured by contrast enhanced MRI at 12 months after initiation of the study 12 months
Secondary QoL Health related Quality of Life; Varni PedsQL, Generic and Diabetes specific questionnaire, by child and proxy (parents or other caregivers) at study start and 12 months after study initiation. 12 months
Secondary Gastrointestinal symptoms Questionnaire on gastrointestinal symptoms: "The gastrointestinal symptom rating scale" (GSRS) at study start and 12 months after study initiation . 12 months
Secondary Time spent eating Average time spent eating at meals during four days in the 12th month after initiation of the study treatment. 12 months
Secondary Intake of saturated fat Intake of saturated fat (E% and if the child reaches Nordic Nutritional Recommendations, NNR) during four days in the 12th month after initiation of the study treatment. four days in the 12th month
Secondary Intake of fruit Intake of fruit and vegetables (g/day and if the child reaches NNR) during four days in the 12th month after initiation of the study treatment. four days in the 12th month
Secondary Intake of macronutrients Intake of macronutrients (E% and g/day) during four days in the 12th month after initiation of the study treatment. four days in the 12th month
Secondary Intake of fibre Intake of fibre (g/day and if the child reaches NNR) during four days in the 12th month after initiation of the study treatment. four days in the 12th month
Secondary Physical activity measured with accelerometer Physical activity registered with accelerometer during one week in the 6th month after initiation of the study treatment. 6 months
Secondary Physical activity measured with accelerometer Physical activity registered with accelerometer during one week in the 12th month after initiation of the study treatment. 12 months
Secondary Oral microbiome The oral microbiome at 12 months after study initiation. 12 months
Secondary Change in stimulated C-peptide Change in stimulated c-peptide two-hour under the curve profile from 6 weeks to 12 months after initiation of study treatment. change from 6 weeks to 12 months after initiation of study treatment
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A